As the Food and Drug Administration considers whether to rescind approval for the breast cancer drug Avastin, one major insurance company has decided against paying for new prescriptions of the medication.
An FDA panel of advisors recommended rescinding approval of Avastin in June. They said it did not appear to help breast cancer patients. Now Blue Cross of California says that as of October 17th, it will no longer pay for Avastin for new breast cancer patients.
However, those already on the drug will be able to continue coverage. Avastin is used to treat other cancers, so it would remain on the market even if its use for breast cancer is rescinded. FDA Commissioner, Margaret Hamburg, has not yet made a final decision.
Copyright 2011 KCBD. All rights reserved